The US Food and Drug Administration on March 8 approved drugmaker Novo Nordisk’s application to add cardiovascular benefits to the medicine’s label, making it the first weight-loss drug to also be cleared to reduce the risk of heart attack, stroke, or heart-related death in people at higher risk of these conditions.